The genetic testing platform detecting and measuring disease.
Do you want to join one of the fastest-growing molecular diagnostics companies to help transform prenatal and oncology diagnostics that can affect millions of patient lives?
BillionToOne (Y Combinator S17), ranked at the top 5% of Y Combinator companies with $100M+ in funding from prominent VC firms, has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold. BillionToOne's first product, UNITY™ is the first and only prenatal screen that directly assesses the baby's risk for common and severe inherited disorders such as cystic fibrosis, spinal muscular atrophy (SMA), and hemoglobinopathies from a single tube of blood from the pregnant mother.
We are looking for a Director of Product Management to lead and manage the prenatal product line (UNITY products). This role will own the entire product roadmap for the prenatal product portfolio by working closely with the R&D, clinical team, engineering team, and company leadership to lead new assay development as well as existing assay enhancements. The ideal candidate has experience in launching molecular diagnostic testing assays, are obsessed with delivering a delightful customer experience, and thrives in a fast-paced entrepreneurial environment, this would be a perfect opportunity for you. This role is a hybrid (onsite 3 days/week) position and reports directly to the SVP of Product.
Benefits and Perks:
BillionToOne is an equal opportunity employer. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold. We are the only technology platform that can detect single-gene disorders in an unborn baby from maternal blood and that can accurately quantify copy number variation (CNV) changes in cancer patients. Our first product, UNITY, is the only NIPT that accurately detects single gene disorders such as cystic fibrosis and sickle cell in the baby from a blood test of the mother. UNITY covers all inherited disorders that every pregnancy needs to be tested for and has 98.5%+ sensitivity and 99%+ specificity.
BillionToOne has recently raised a large Series A funding from global institutional investors, including from Hummingbird Ventures, NeoTribe Ventures and Y Combinator: https://www.genomeweb.com/molecular-diagnostics/prenatal-testing-firm-billiontoone-closes-15m-series-financing
Check out a simplified introduction to our technology and its potential to transform molecular diagnostics: